Loughlin AM, et al. - The researchers compared the effectiveness and tolerability of exenatide once-weekly (EQW) vs basal insulin (BI) among injectable-naïve elderly or renal impairment (RI) patients with type 2 diabetes in the United States. Compared to BI treatment, the benefits of EQW were improved glycemic control and increased weight loss, regardless of age or renal function. This ought to be weighed against the increased risk of gastrointestinal symptoms.